Waupun Regional Dialysis is a medicare approved dialysis facility center in Waupun, Wisconsin and it has 12 dialysis stations. It is located in Dodge county at 10 Beaver Dam St, Waupun, WI, 53963. You can reach out to the office of Waupun Regional Dialysis at (920) 324-6531. This dialysis clinic is run as an Independent entity i.e it is not owned by any chain organization. Waupun Regional Dialysis has the following ownership type - Non-Profit. It was first certified by medicare in September, 1977. The medicare id for this facility is 520025 and it accepts patients under medicare ESRD program.
| Name | Waupun Regional Dialysis |
|---|---|
| Location | 10 Beaver Dam St, Waupun, Wisconsin |
| No. of Dialysis Stations | 12 |
| Medicare ID | 520025 |
| Managed By | Independent |
| Ownership Type | Non-Profit |
| Late Shifts | No |
| 10 Beaver Dam St, Waupun, Wisconsin, 53963 | |
| (920) 324-6531 | |
News Archive
Seldom can one say $3.8 million is just the tip of the iceberg, but a newly awarded grant from Gilead Sciences, Inc. is just that. MUSC transplant surgeon Kenneth Chavin, M.D., Ph.D., says the true value of the multi-center drug trial is closer to $26 million, including $22 million in free drugs provided by the pharmaceutical company.
University of Texas at Austin sociologist Chandra Muller and economist Sandra Black have received a $3.2 million grant from the Alfred P. Sloan Foundation to study the effects of cognition on health, mortality, education and employment from high school and beyond.
Implantation of a sleep apnea device called Inspire- Upper Airway Stimulation therapy can lead to significant improvements for patients with obstructive sleep apnea, according to a study published today in the New England Journal of Medicine.
Ligand Pharmaceuticals Incorporated today announced that the U.S. Food and Drug Administration has granted its partner GlaxoSmithKline plc Breakthrough Therapy designation for Promacta/Revolade (eltrombopag) for the treatment of cytopenias in patients with severe aplastic anemia (SAA) who have had insufficient response to immunosuppressive therapy.
› Verified 2 days ago
| NPI Number | 1760460877 |
| Organization Name | Waupun Dialysis Center |
| Doing Business As | Waupun Memorial Hospital |
| Address | 10 Beaver Dam St Waupun, Wisconsin, 53963 |
| Phone Number | (920) 324-5581 |
News Archive
Seldom can one say $3.8 million is just the tip of the iceberg, but a newly awarded grant from Gilead Sciences, Inc. is just that. MUSC transplant surgeon Kenneth Chavin, M.D., Ph.D., says the true value of the multi-center drug trial is closer to $26 million, including $22 million in free drugs provided by the pharmaceutical company.
University of Texas at Austin sociologist Chandra Muller and economist Sandra Black have received a $3.2 million grant from the Alfred P. Sloan Foundation to study the effects of cognition on health, mortality, education and employment from high school and beyond.
Implantation of a sleep apnea device called Inspire- Upper Airway Stimulation therapy can lead to significant improvements for patients with obstructive sleep apnea, according to a study published today in the New England Journal of Medicine.
Ligand Pharmaceuticals Incorporated today announced that the U.S. Food and Drug Administration has granted its partner GlaxoSmithKline plc Breakthrough Therapy designation for Promacta/Revolade (eltrombopag) for the treatment of cytopenias in patients with severe aplastic anemia (SAA) who have had insufficient response to immunosuppressive therapy.
› Verified 2 days ago
| Dialysis patients with Hemoglobin data | 12 |
| Medicare patients who had average hemoglobin (hgb) less than 10 g/dL | 8 |
News Archive
Seldom can one say $3.8 million is just the tip of the iceberg, but a newly awarded grant from Gilead Sciences, Inc. is just that. MUSC transplant surgeon Kenneth Chavin, M.D., Ph.D., says the true value of the multi-center drug trial is closer to $26 million, including $22 million in free drugs provided by the pharmaceutical company.
University of Texas at Austin sociologist Chandra Muller and economist Sandra Black have received a $3.2 million grant from the Alfred P. Sloan Foundation to study the effects of cognition on health, mortality, education and employment from high school and beyond.
Implantation of a sleep apnea device called Inspire- Upper Airway Stimulation therapy can lead to significant improvements for patients with obstructive sleep apnea, according to a study published today in the New England Journal of Medicine.
Ligand Pharmaceuticals Incorporated today announced that the U.S. Food and Drug Administration has granted its partner GlaxoSmithKline plc Breakthrough Therapy designation for Promacta/Revolade (eltrombopag) for the treatment of cytopenias in patients with severe aplastic anemia (SAA) who have had insufficient response to immunosuppressive therapy.
› Verified 2 days ago
Adult patinets who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be atleast 1.7, that means they are receiving right amount of dialysis. Pediatric patients who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be 1.8.
Higher percentages should be better.
| Adult patients getting regular hemodialysis at the center | 23 |
| Adult patient months included in Kt/V greater than or equal to 1.2 | 202 |
| Percentage of adult patients getting regular hemodialysis at the center | 100 |
| Percentage of pediatric patients getting regular hemodialysis at the center |
News Archive
Seldom can one say $3.8 million is just the tip of the iceberg, but a newly awarded grant from Gilead Sciences, Inc. is just that. MUSC transplant surgeon Kenneth Chavin, M.D., Ph.D., says the true value of the multi-center drug trial is closer to $26 million, including $22 million in free drugs provided by the pharmaceutical company.
University of Texas at Austin sociologist Chandra Muller and economist Sandra Black have received a $3.2 million grant from the Alfred P. Sloan Foundation to study the effects of cognition on health, mortality, education and employment from high school and beyond.
Implantation of a sleep apnea device called Inspire- Upper Airway Stimulation therapy can lead to significant improvements for patients with obstructive sleep apnea, according to a study published today in the New England Journal of Medicine.
Ligand Pharmaceuticals Incorporated today announced that the U.S. Food and Drug Administration has granted its partner GlaxoSmithKline plc Breakthrough Therapy designation for Promacta/Revolade (eltrombopag) for the treatment of cytopenias in patients with severe aplastic anemia (SAA) who have had insufficient response to immunosuppressive therapy.
› Verified 2 days ago
An important goal of dialysis is to maintain normal levels of various minerals in the body, such as calcium. This shows the percentage of patients treated at Waupun Regional Dialysis with elevated calcium levels.
| Patients with hypercalcemia | 24 |
| Hypercalcemia patient months | 214 |
| Patients with Serumphosphor | 26 |
| Patients with Serumphosphor less than 3.5 mg/dL | 5 |
| Patients with Serumphosphor from 3.5 to 4.5 mg/dL | 27 |
| Patients with Serumphosphor from 4.6 to 5.5 mg/dL | 23 |
| Patients with Serumphosphor from 5.6 to 7 mg/dL | 24 |
| Patients with Serumphosphor greater than 7 mg/dL | 21 |
News Archive
Seldom can one say $3.8 million is just the tip of the iceberg, but a newly awarded grant from Gilead Sciences, Inc. is just that. MUSC transplant surgeon Kenneth Chavin, M.D., Ph.D., says the true value of the multi-center drug trial is closer to $26 million, including $22 million in free drugs provided by the pharmaceutical company.
University of Texas at Austin sociologist Chandra Muller and economist Sandra Black have received a $3.2 million grant from the Alfred P. Sloan Foundation to study the effects of cognition on health, mortality, education and employment from high school and beyond.
Implantation of a sleep apnea device called Inspire- Upper Airway Stimulation therapy can lead to significant improvements for patients with obstructive sleep apnea, according to a study published today in the New England Journal of Medicine.
Ligand Pharmaceuticals Incorporated today announced that the U.S. Food and Drug Administration has granted its partner GlaxoSmithKline plc Breakthrough Therapy designation for Promacta/Revolade (eltrombopag) for the treatment of cytopenias in patients with severe aplastic anemia (SAA) who have had insufficient response to immunosuppressive therapy.
› Verified 2 days ago
The arteriovenous (AV) fistulae is considered long term vascular access for hemodialysis because it allows good blood flow, lasts a long time, and is less likely to get infected or cause blood clots than other types of access. Patients who don't have time to get a permanent vascular access before they start hemodialysis treatments may need to use a venous catheter as a temporary access.
| Patients included in arterial venous fistula and catheter summaries | 18 |
| Patient months included in arterial venous fistula and catheter summaries | 157 |
| Percentage of patients getting regular hemodialysis at the center that used an arteriovenous (AV) fistulae for their treatment | 80 |
| Percentage of patients receiving treatment through Vascular Catheter for 90 days/longer | 18 |
News Archive
Seldom can one say $3.8 million is just the tip of the iceberg, but a newly awarded grant from Gilead Sciences, Inc. is just that. MUSC transplant surgeon Kenneth Chavin, M.D., Ph.D., says the true value of the multi-center drug trial is closer to $26 million, including $22 million in free drugs provided by the pharmaceutical company.
University of Texas at Austin sociologist Chandra Muller and economist Sandra Black have received a $3.2 million grant from the Alfred P. Sloan Foundation to study the effects of cognition on health, mortality, education and employment from high school and beyond.
Implantation of a sleep apnea device called Inspire- Upper Airway Stimulation therapy can lead to significant improvements for patients with obstructive sleep apnea, according to a study published today in the New England Journal of Medicine.
Ligand Pharmaceuticals Incorporated today announced that the U.S. Food and Drug Administration has granted its partner GlaxoSmithKline plc Breakthrough Therapy designation for Promacta/Revolade (eltrombopag) for the treatment of cytopenias in patients with severe aplastic anemia (SAA) who have had insufficient response to immunosuppressive therapy.
› Verified 2 days ago
The rate of hospitalization show you whether patients who were being treated regularly at a certain dialysis center were admitted to the hospital more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other centers.
| Standard Hospitalization Summary Ratio(SHR) Year | January, 2016 - December, 2016 |
| Patients in facility's Hospitalization Summary | 24 |
| Hospitalization Rate in facility | 120.9 (As Expected) |
| Hospitalization Rate: Upper Confidence Limit | 313.6 |
| Hospitalization Rate: Lower Confidence Limit | 50.2 |
News Archive
Seldom can one say $3.8 million is just the tip of the iceberg, but a newly awarded grant from Gilead Sciences, Inc. is just that. MUSC transplant surgeon Kenneth Chavin, M.D., Ph.D., says the true value of the multi-center drug trial is closer to $26 million, including $22 million in free drugs provided by the pharmaceutical company.
University of Texas at Austin sociologist Chandra Muller and economist Sandra Black have received a $3.2 million grant from the Alfred P. Sloan Foundation to study the effects of cognition on health, mortality, education and employment from high school and beyond.
Implantation of a sleep apnea device called Inspire- Upper Airway Stimulation therapy can lead to significant improvements for patients with obstructive sleep apnea, according to a study published today in the New England Journal of Medicine.
Ligand Pharmaceuticals Incorporated today announced that the U.S. Food and Drug Administration has granted its partner GlaxoSmithKline plc Breakthrough Therapy designation for Promacta/Revolade (eltrombopag) for the treatment of cytopenias in patients with severe aplastic anemia (SAA) who have had insufficient response to immunosuppressive therapy.
› Verified 2 days ago
The rate of readmission show you whether patients who were being treated regularly at Waupun Regional Dialysis were readmitted more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other dialysis centers.
| Standard Readmission Summary Ratio(SRR) Year | January, 2016 - December, 2016 |
| Readmission Rate in facility | 12.4 (As Expected) |
| Readmission Rate: Upper Confidence Limit | 54.7 |
| Readmission Rate: Lower Confidence Limit | .5 |
News Archive
Seldom can one say $3.8 million is just the tip of the iceberg, but a newly awarded grant from Gilead Sciences, Inc. is just that. MUSC transplant surgeon Kenneth Chavin, M.D., Ph.D., says the true value of the multi-center drug trial is closer to $26 million, including $22 million in free drugs provided by the pharmaceutical company.
University of Texas at Austin sociologist Chandra Muller and economist Sandra Black have received a $3.2 million grant from the Alfred P. Sloan Foundation to study the effects of cognition on health, mortality, education and employment from high school and beyond.
Implantation of a sleep apnea device called Inspire- Upper Airway Stimulation therapy can lead to significant improvements for patients with obstructive sleep apnea, according to a study published today in the New England Journal of Medicine.
Ligand Pharmaceuticals Incorporated today announced that the U.S. Food and Drug Administration has granted its partner GlaxoSmithKline plc Breakthrough Therapy designation for Promacta/Revolade (eltrombopag) for the treatment of cytopenias in patients with severe aplastic anemia (SAA) who have had insufficient response to immunosuppressive therapy.
› Verified 2 days ago
Hemodialysis treatment requires direct access to the bloodstream, which can be an opportunity for germs to enter the body and cause infection. This information shows how often patients at Waupun Regional Dialysis get infections in their blood each year compared to the number of infections expected for the center based on the national average.
| Standard Infection Summary Ratio(SIR) Year | January, 2016 - December, 2016 |
| Infection Rate in facility | 1.27 (As Expected) |
| SIR: Upper Confidence Limit | 3.46 |
| SIR: Lower Confidence Limit | .32 |
News Archive
Seldom can one say $3.8 million is just the tip of the iceberg, but a newly awarded grant from Gilead Sciences, Inc. is just that. MUSC transplant surgeon Kenneth Chavin, M.D., Ph.D., says the true value of the multi-center drug trial is closer to $26 million, including $22 million in free drugs provided by the pharmaceutical company.
University of Texas at Austin sociologist Chandra Muller and economist Sandra Black have received a $3.2 million grant from the Alfred P. Sloan Foundation to study the effects of cognition on health, mortality, education and employment from high school and beyond.
Implantation of a sleep apnea device called Inspire- Upper Airway Stimulation therapy can lead to significant improvements for patients with obstructive sleep apnea, according to a study published today in the New England Journal of Medicine.
Ligand Pharmaceuticals Incorporated today announced that the U.S. Food and Drug Administration has granted its partner GlaxoSmithKline plc Breakthrough Therapy designation for Promacta/Revolade (eltrombopag) for the treatment of cytopenias in patients with severe aplastic anemia (SAA) who have had insufficient response to immunosuppressive therapy.
› Verified 2 days ago
Patients with anemia require blood transfusions if their anemia is not managed well by their dialysis center. This information shows whether Waupun Regional Dialysis's rate of transfusions is better than expected, as expected, or worse than expected, compared to other centers that treat similar patients.
| Standard Transfusion Summary Ratio (STrR) Year | January, 2016 - December, 2016 |
| Patients in facility's Transfusion Summary | 24 |
| Transfusion Rate in facility | 23.2 (As Expected) |
| Transfusion Rate: Upper Confidence Limit | 136 |
| Transfusion Rate: Lower Confidence Limit | 4.9 |
News Archive
Seldom can one say $3.8 million is just the tip of the iceberg, but a newly awarded grant from Gilead Sciences, Inc. is just that. MUSC transplant surgeon Kenneth Chavin, M.D., Ph.D., says the true value of the multi-center drug trial is closer to $26 million, including $22 million in free drugs provided by the pharmaceutical company.
University of Texas at Austin sociologist Chandra Muller and economist Sandra Black have received a $3.2 million grant from the Alfred P. Sloan Foundation to study the effects of cognition on health, mortality, education and employment from high school and beyond.
Implantation of a sleep apnea device called Inspire- Upper Airway Stimulation therapy can lead to significant improvements for patients with obstructive sleep apnea, according to a study published today in the New England Journal of Medicine.
Ligand Pharmaceuticals Incorporated today announced that the U.S. Food and Drug Administration has granted its partner GlaxoSmithKline plc Breakthrough Therapy designation for Promacta/Revolade (eltrombopag) for the treatment of cytopenias in patients with severe aplastic anemia (SAA) who have had insufficient response to immunosuppressive therapy.
› Verified 2 days ago
The rate of mortality show you whether patients who were being treated regularly at Waupun Regional Dialysis lived longer than expected (better than expected), don’t live as long as expected (worse than expected), or lived as long as expected (as expected), compared to similar patients treated at other facilities.
| Standard Survival Summary Ratio(SIR) Year | January, 2013 - December, 2016 |
| Patients in facility's Survival Summary | 144 |
| Mortality Rate in facility | 12.8 (As Expected) |
| Mortality Rate: Upper Confidence Limit | 19.6 |
| Mortality Rate: Lower Confidence Limit | 7.9 |
News Archive
Seldom can one say $3.8 million is just the tip of the iceberg, but a newly awarded grant from Gilead Sciences, Inc. is just that. MUSC transplant surgeon Kenneth Chavin, M.D., Ph.D., says the true value of the multi-center drug trial is closer to $26 million, including $22 million in free drugs provided by the pharmaceutical company.
University of Texas at Austin sociologist Chandra Muller and economist Sandra Black have received a $3.2 million grant from the Alfred P. Sloan Foundation to study the effects of cognition on health, mortality, education and employment from high school and beyond.
Implantation of a sleep apnea device called Inspire- Upper Airway Stimulation therapy can lead to significant improvements for patients with obstructive sleep apnea, according to a study published today in the New England Journal of Medicine.
Ligand Pharmaceuticals Incorporated today announced that the U.S. Food and Drug Administration has granted its partner GlaxoSmithKline plc Breakthrough Therapy designation for Promacta/Revolade (eltrombopag) for the treatment of cytopenias in patients with severe aplastic anemia (SAA) who have had insufficient response to immunosuppressive therapy.
› Verified 2 days ago
News Archive
Seldom can one say $3.8 million is just the tip of the iceberg, but a newly awarded grant from Gilead Sciences, Inc. is just that. MUSC transplant surgeon Kenneth Chavin, M.D., Ph.D., says the true value of the multi-center drug trial is closer to $26 million, including $22 million in free drugs provided by the pharmaceutical company.
University of Texas at Austin sociologist Chandra Muller and economist Sandra Black have received a $3.2 million grant from the Alfred P. Sloan Foundation to study the effects of cognition on health, mortality, education and employment from high school and beyond.
Implantation of a sleep apnea device called Inspire- Upper Airway Stimulation therapy can lead to significant improvements for patients with obstructive sleep apnea, according to a study published today in the New England Journal of Medicine.
Ligand Pharmaceuticals Incorporated today announced that the U.S. Food and Drug Administration has granted its partner GlaxoSmithKline plc Breakthrough Therapy designation for Promacta/Revolade (eltrombopag) for the treatment of cytopenias in patients with severe aplastic anemia (SAA) who have had insufficient response to immunosuppressive therapy.
› Verified 2 days ago